China Approves First mRNA Vaccine

CSBC Group Pharmaceuticals confirmed today, Wednesday, that its messenger RNA (mRNA) vaccine against COVID-19 has received emergency use authorization from Chinese health authorities, making it the first vaccine of this type developed locally in the country. The company stated that trials conducted on the vaccine showed significantly lower instances of side effects in the elderly compared to adults. This is advantageous for China, which emphasizes vaccinating at-risk seniors. China has rejected the use of mRNA vaccines produced abroad.